Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Pfizer Goes For An IPO

Executive Summary

Pfizer’s strategy is to monetize part of its animal health division while continuing new CEO Ian Read’s increased focus on biopharmaceuticals.

You may also be interested in...



Pfizer’s Redmond Surfs To WebMD, With Consumer Health Future In Mind

Cavan Redmond left his role as Pfizer group president, with responsibility for consumer healthcare, to become CEO of the online health information provider May 31. The pharma veteran sees WebMD at the intersection of enabling consumers and physicians to make health care decisions.

Pfizer’s Redmond Surfs To WebMD, With Consumer Health Future In Mind

Cavan Redmond left his role as Pfizer group president, with responsibility for consumer healthcare, to become CEO of the online health information provider May 31. The pharma veteran sees WebMD at the intersection of enabling consumers and physicians to make health care decisions.

Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel